GlobeNewswire·Jun 18, 2026, 8:46 AM ET

CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026

CytoSorbents Corporation (NASDAQ: CTSO) will present at the VirtualInvestorConferences.com Life Sciences Forum on Wednesday, June 24, 2026, at 11:30 AM EDT.
CEO Dr. Phillip Chan will provide an overview of the company, followed by a Q&A session with Zacks Analyst Thomas Kerr & CFO Peter Mariani.
One-on-one meetings with registered investors are scheduled for Tuesday, June 30, 2026.
CytoSorbents develops blood purification technologies using biocompatible polymer beads to remove toxins, inflammatory agents, & blood thinners from bodily fluids.
The lead product CytoSorb® is approved in the European Union & distributed in over 70 countries, with more than 300,000 devices used cumulatively.
CytoSorb® holds FDA Emergency Use Authorization for adult critically ill COVID-19 patients in the U.S., though it lacks full U.S. approval.
The company is developing DrugSorb®-ATR in the U.S. & Canada to remove blood thinners during cardiothoracic surgery; it has received two FDA Breakthrough Device Designations but remains unapproved.
CytoSorbents aims to achieve cash-flow break-even in the second half of 2026 while pursuing regulatory approvals from the U.S. FDA & Health Canada.
Forward-looking statements in the release highlight risks including restructuring in Germany, financing needs, & potential delays in regulatory submissions.